SOAT1 and myeloproliferative disorder: ,2 JAK inhibitors are used to treat myeloproliferative disorders such as polycythemia vera and inflammatory disorders such as rheumatoid arthritis and ulcerative colitis,2 reflecting the central role of JAK-STAT signaling in these diseases.